These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives. Candelaria M; Taja-Chayeb L; Arce-Salinas C; Vidal-Millan S; Serrano-Olvera A; Dueñas-Gonzalez A Anticancer Drugs; 2005 Oct; 16(9):923-33. PubMed ID: 16162969 [TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Bosch TM; Meijerman I; Beijnen JH; Schellens JH Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759 [TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics. Quaranta S; Thomas F Therapie; 2017 Apr; 72(2):205-215. PubMed ID: 28262261 [TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Sekine I; Saijo N Ann Oncol; 2001 Nov; 12(11):1515-25. PubMed ID: 11822749 [TBL] [Abstract][Full Text] [Related]
10. Cancer pharmacogenomics: current and future applications. Watters JW; McLeod HL Biochim Biophys Acta; 2003 Mar; 1603(2):99-111. PubMed ID: 12618310 [TBL] [Abstract][Full Text] [Related]
11. Drug metabolizing enzymes and their inhibitors' role in cancer resistance. Pathania S; Bhatia R; Baldi A; Singh R; Rawal RK Biomed Pharmacother; 2018 Sep; 105():53-65. PubMed ID: 29843045 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy]. Hasegawa Y Gan To Kagaku Ryoho; 2003 Mar; 30(3):325-33. PubMed ID: 12669388 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics of cancer chemotherapy-induced toxicity. Miller CR; McLeod HL J Support Oncol; 2007 Jan; 5(1):9-14. PubMed ID: 17265780 [TBL] [Abstract][Full Text] [Related]
14. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267 [TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacogenetics and potential application in personalized medicine. Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics and individualized drug therapy. Eichelbaum M; Ingelman-Sundberg M; Evans WE Annu Rev Med; 2006; 57():119-37. PubMed ID: 16409140 [TBL] [Abstract][Full Text] [Related]
17. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Maitland ML; Vasisht K; Ratain MJ Trends Pharmacol Sci; 2006 Aug; 27(8):432-7. PubMed ID: 16815558 [TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of thiopurine S-methyltransferase gene polymorphisms. Mladosievicova B; Dzurenkova A; Sufliarska S; Carter A Neoplasma; 2011; 58(4):277-82. PubMed ID: 21520983 [TBL] [Abstract][Full Text] [Related]
19. Personalizing chemotherapy dosing using pharmacological methods. Patel JN; Papachristos A Cancer Chemother Pharmacol; 2015 Nov; 76(5):879-96. PubMed ID: 26298089 [TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of cytotoxic drugs. Daly AK; Hall AG Expert Rev Anticancer Ther; 2001 Aug; 1(2):301-8. PubMed ID: 12113035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]